Lurbinectedin (LUR) in combination with irinotecan (IRI) in patients (pts) with advanced solid tumours
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz244.033
Abstract: Abstract Background LUR is a new agent that exerts antitumor activity through inhibition of trans-activated transcription and modulation of tumor microenvironment. Preclinical synergism/additivity in combination with IRI has been reported, thus prompting the conduct of… read more here.
Keywords: time employment; full part; iri; pharmamar ... See more keywords